Rimegepant Approved for Preventive Treatment of Migraine, Adding to Acute Indication

"The FDA approval of Nurtec ODT for the preventive treatment of migraine—along with its acute treatment indication—is one of the most groundbreaking things to happen to migraine treatment in my 40 years of practicing headache medicine," Peter J. Goadsby, MD, PhD, DSc, professor of neurology, University of California, Los Angeles, and King's College London, and co-author of the phase 3 preventive study, said in a statement.1 "To have one medication patients can use to treat and prevent migraine will likely change the treatment paradigm for many of the millions of people who live with migraine." Additionally, of those in the rimegepant group, 49.1% reported at least a 50% reduction from the baseline number of moderate to severe migraine days compared to 41.5% in the placebo group (P